Almirall (LBTSF) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free LBTSF Stock Alerts $9.51 +0.22 (+2.37%) (As of 01/26/2024) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:30 AM | americanbankingnews.comAlmirall, S.A. (OTCMKTS:LBTSF) Short Interest UpdateMay 13, 2024 | marketwatch.comAlmirall Shares Rise After Confirmed Targets, Revenue IncreaseFebruary 20, 2024 | msn.comAlmirall, S.A. reports FY resultsFebruary 19, 2024 | finance.yahoo.comAlmirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology businessFebruary 5, 2024 | msn.comAlmirall and Microsoft partner on AI-powered drug discovery in dermatologyDecember 12, 2023 | marketwatch.comAlmirall, Etherna Team Up to Develop MRNA-Based Dermatology TherapiesDecember 12, 2023 | finance.yahoo.comAlmirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical DermatologyNovember 17, 2023 | marketwatch.comAlmirall Shares Rise on European Approval for Skin DrugNovember 17, 2023 | finance.yahoo.comAlmirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic DermatitisNovember 15, 2023 | msn.comAlmirall and Absci partner on AI-driven dermatological drug developmentNovember 14, 2023 | finanznachrichten.deAbsci Corporation: Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | finance.yahoo.comAlmirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | msn.comAbsci, Almirall partner on dermatologic drug developmentNovember 9, 2023 | msn.comAlmirall, S.A. reports 9M resultsNovember 9, 2023 | businesswire.comAlmirall’s Nine-month 2023 Results:October 13, 2023 | businesswire.comAlmirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for CyclosporineOctober 12, 2023 | msn.comAlmirall and EpimAb partner to develop bispecific antibody therapiesOctober 12, 2023 | businesswire.comEpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License AgreementOctober 11, 2023 | finance.yahoo.comAlmirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque PsoriasisOctober 10, 2023 | businesswire.comCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaSeptember 18, 2023 | msn.comEMA’s CHMP supports Almirall’s Ebyglyss for atopic dermatitisJuly 24, 2023 | msn.comAlmirall, S.A. reports 1H resultsJuly 7, 2023 | finance.yahoo.comAlmirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasisJune 13, 2023 | finance.yahoo.comAlmirall announces the pricing and closing of its €200mm non pre-emptive share capital increaseMay 8, 2023 | news.yahoo.comAlmirall's Q1 core earnings beat estimates on Europe dermatology operationsMay 8, 2023 | reuters.comAlmirall's core earnings beat estimates in Q1May 8, 2023 | finance.yahoo.comAlmirall’s First Quarter 2023 ResultsMay 1, 2023 | finance.yahoo.comAlmirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New AnalysisApril 21, 2023 | msn.comCREDIT SUISSE - EUROPE Maintains Almirall (XMAD:ALM) Neutral RecommendationApril 13, 2023 | finance.yahoo.comAlmirall, S.A. (ALM.MC)April 12, 2023 | finance.yahoo.comAlmirall, The First to Assess Wellbeing in a Dermatology Clinical StudyFebruary 20, 2023 | marketwatch.comAlmirall Shares Rise on Swing to 2022 Net Profit, CEO ConfirmationFebruary 20, 2023 | reuters.comSpain's Almirall expects core earnings to fall in 2023January 4, 2023 | nz.finance.yahoo.comAlmirall to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceNovember 10, 2022 | msn.comSpain's Almirall Q3 core earnings fall 13%; keeps outlookOctober 3, 2022 | seekingalpha.comWeek In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million ValueSeptember 29, 2022 | benzinga.comSimcere and Almirall Enter into a Licensing Agreement for IL-2 mu-FcAugust 18, 2022 | finance.yahoo.comAlmirall's Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline updateJuly 26, 2022 | seekingalpha.comAlmirall, S.A. 2022 Q2 - Results - Earnings Call PresentationJuly 25, 2022 | seekingalpha.comAlmirall, S.A. (LBTSF) CEO Gianfranco Nazzi on Q2 2022 Results - Earnings Call TranscriptJuly 25, 2022 | msn.comSpain's Almirall returns to profitability in first half as sales growJune 13, 2022 | finance.yahoo.comHappify Health and Almirall Go Live with Digital Solution to Support Psoriasis PatientsJune 7, 2022 | finanznachrichten.deAlmirall, S.A.: Almirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy TrialsJune 7, 2022 | finance.yahoo.comAlmirall: Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy TrialsMay 19, 2022 | seekingalpha.comEvotec, Almirall team up to discover therapies for skin diseasesMay 19, 2022 | finanznachrichten.deEvotec AG: Evotec and Almirall Enter into a Multi-Target Alliance in Medical DermatologyMay 19, 2022 | markets.businessinsider.comDGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatologyMay 19, 2022 | nasdaq.comEvotec Announces Collaboration With AlmirallMay 9, 2022 | seekingalpha.comAlmirall, S.A. (LBTSF) CEO Gianfranco Nazzi on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | nasdaq.comSpain's Almirall confirms 2022 target after first quarter profit drop Get Almirall News Delivered to You Automatically Sign up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit LBTSF Media Mentions By Week LBTSF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LBTSF News Sentiment▼0.900.42▲Average Medical News Sentiment LBTSF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LBTSF Articles This Week▼20▲LBTSF Articles Average Week Get Almirall News Delivered to You Automatically Sign up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TGIFF News FFNTF News ABSCF News ACRDF News ACRHF News ALEAF News AZFL News ERBB News AVTBF News AVCNF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LBTSF) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Almirall, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
